Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
Tandem Diabetes Care reported Q3 2026 worldwide sales of $283.7 million, up 14% year-over-year, with U.S. sales up 9% to $191.0 million and international sales up 26% to $92.6 million. Margins improved markedly: gross margin rose 270bps to 57%, operating loss narrowed to $2.4 million from $22.9 million, and adjusted EBITDA jumped to $18.0 million from $2.8 million, though the company still posted a $7.1 million net loss and negative free cash flow of $5.5 million. Strategic progress included pharmacy formulary coverage reaching roughly 50% of U.S.
Key figures
- Revenue
- 283690000
- Guidance
- FY2026 sales approximately $1.065B-$1.085B (US $730M-$745M, International $335M-$340M); gross margin ~56%-57%; adjusted EBITDA margin ~5%-6%
- Revenue Yoy
- 14%
- Us sales
- 191045000
- Gross margin
- 57%
- Pump shipments
- approximately 33,000 worldwide
- Adjusted ebitda
- 18037000
- International sales
- 92645000
- Cash and investments
- 443082000
- Adjusted ebitda margin
- 6%
- Pharmacy channel pct of us sales
- 15%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.